Dan Roden
Faculty Member
Last active: 2/8/2016

  1. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, Yue P, Tsao PS, Tsau PS, Kohane I, Roden DM, Altman RB (2011) Clin Pharmacol Ther 90(1): 133-42
    › Primary publication · 21613990 (PubMed) · PMC3216673 (PubMed Central)
  2. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR, Clinical Pharmacogenetics Implementation Consortium (2011) Clin Pharmacol Ther 90(2): 328-32
    › Primary publication · 21716271 (PubMed) · PMC3234301 (PubMed Central)
  3. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG (2011) PLoS One 6(11): e27808
    › Primary publication · 22114699 (PubMed) · PMC3218053 (PubMed Central)
  4. Cardiovascular pharmacogenomics. Roden DM, Johnson JA, Kimmel SE, Krauss RM, Medina MW, Shuldiner A, Wilke RA (2011) Circ Res 109(7): 807-20
    › Primary publication · 21921273 (PubMed) · PMC3201825 (PubMed Central)
  5. Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. Barrett TW, Storrow AB, Jenkins CA, Harrell FE, Miller KF, Moser KM, Russ S, Roden DM, Darbar D (2011) J Cardiol 58(2): 124-30
    › Primary publication · 21820279 (PubMed) · PMC3169197 (PubMed Central)
  6. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Holm H, Gudbjartsson DF, Sulem P, Masson G, Helgadottir HT, Zanon C, Magnusson OT, Helgason A, Saemundsdottir J, Gylfason A, Stefansdottir H, Gretarsdottir S, Matthiasson SE, Thorgeirsson GM, Jonasdottir A, Sigurdsson A, Stefansson H, Werge T, Rafnar T, Kiemeney LA, Parvez B, Muhammad R, Roden DM, Darbar D, Thorleifsson G, Walters GB, Kong A, Thorsteinsdottir U, Arnar DO, Stefansson K (2011) Nat Genet 43(4): 316-20
    › Primary publication · 21378987 (PubMed) · PMC3066272 (PubMed Central)
  7. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G, Castro RA, Johns SJ, Stryke D, Sali A, Ferrin TE, Witte JS, Kwok PY, Roden DM, Wilke RA, McCarty CA, Davis RL, Giacomini KM (2011) Clin Pharmacol Ther 90(5): 674-84
    › Primary publication · 21956618 (PubMed) · PMC3329222 (PubMed Central)
  8. A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation. Barrett TW, Martin AR, Storrow AB, Jenkins CA, Harrell FE, Russ S, Roden DM, Darbar D (2011) Ann Emerg Med 57(1): 1-12
    › Primary publication · 20728962 (PubMed) · PMC3008754 (PubMed Central)
  9. Voltage-gated sodium channels are required for heart development in zebrafish. Chopra SS, Stroud DM, Watanabe H, Bennett JS, Burns CG, Wells KS, Yang T, Zhong TP, Roden DM (2010) Circ Res 106(8): 1342-50
    › Primary publication · 20339120 (PubMed) · PMC2869449 (PubMed Central)
  10. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow RO, Buxton AE, Chen PS, Estes M, Jouven X, Kwong R, Lathrop DA, Mascette AM, Nerbonne JM, O'Rourke B, Page RL, Roden DM, Rosenbaum DS, Sotoodehnia N, Trayanova NA, Zheng ZJ (2010) Circulation 122(22): 2335-48
    › Primary publication · 21147730 (PubMed) · PMC3016224 (PubMed Central)